$ARPO News

Last published 5y ago

5y agoARPOAerpio Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireEnded second quarter 2021 with $36.8 million in cash and cash equivalents On May 16, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc., which is subject to the approval of Aerpio shareholders and other customary clos
5y agoACOR ARPO AVXL OCGN+1Thinking about buying stock in Acorda Therapeutics, Ocular Therapeutix, Ocugen, Aerpio Pharmaceuticals, or Anavex Life Sciences?PR NewswireNEW YORK, July 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACOR, OCUL, OCGN, ARPO, and AVXL.
5y agoARPO COF CSX LU+1Thinking about buying stock in Aerpio Pharmaceuticals, Lufax, Verb Technology, CSX Corp, or Capital One Financial?PR NewswireNEW YORK, July 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARPO, LU, VERB, CSX, and COF. To see
5y agoARPO CXDO ECOR GAN+1Thinking about buying stock in Aerpio Pharmaceuticals, Gan, electroCore, Crexendo, or TESSCO Technologies?PR NewswireNEW YORK, July 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARPO, GAN, ECOR, CXDO, and TESS. To
5y agoARPOAerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual MeetingGlobeNewswireCINCINNATI, June 04, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO) announced that Aadi Bioscience, Inc. ("Aadi"), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cance
5y agoAMC ARPO BB CGC+1Thinking about buying stock in BlackBerry, Sundial Growers, AMC, Canopy Growth Corp, or Aerpio Pharmaceuticals?PR NewswireNEW YORK, May 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BB, SNDL, AMC, CGC, and ARPO. To se
5y agoARPO F KT PROG+1Thinking about buying stock in SCYNEXIS, Ford, Aerpio Pharmaceuticals, KT Corp, or Progenity?PR NewswireNEW YORK, May 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SCYX, F, ARPO, KT, and PROG. To see
5y agoARPOAerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual MeetingGlobeNewswireCINCINNATI, May 19, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (NASDAQ:ARPO) announced that Aadi Bioscience ("Aadi"), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with
5y agoAMC ARPO ATER DISCA+1Thinking about buying stock in Discovery, AT&T, AMC Entertainment, Aterian, or Aerpio Pharmaceuticals?PR NewswireNEW YORK, May 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DISCA, T, AMC, ATER, and ARPO. To se
5y agoARPOAerpio Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireEnded first quarter 2021 with $39.0 million in cash and cash equivalents Subsequent to March 31, 2021, Aerpio entered into an agreement and plan of merger with Aadi Bioscience, Inc. CINCINNATI, May 17, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuti
5y agoARPOAerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger AgreementGlobeNewswireTransaction to create Nasdaq-listed company focused on advancing Aadi Bioscience's late-stage pipeline for genetically-defined cancers with alterations in mTOR pathway genes Concurrent $155 million PIPE financing is backed by leading life science inves
5y agoARPOAerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateGlobeNewswireEnded fourth quarter 2020 with $42.6 million in cash and cash equivalents Aerpio is currently evaluating a range of strategic alternatives focused on maximizing stockholder value from existing...
5y agoARPOQuantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID TrialGlobeNewswireSAN FRANCISCO and CINCINNATI, March 05, 2021 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the...
5y agoARPOAerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 TrialGlobeNewswireCINCINNATI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2,...
5y agoARPONew patent application published for: Formulations of Tie-2 Activators and Methods of Use ThereofUS Patent Applications (USPTO)
5y agoARPO GOSSAerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 TrialGlobeNewswirePrimary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group. Patient enrollment and dosing continues in both COVID-19 clinical trials ...
5y agoARPONew patent application published for: Compositions, Formulations and Methods for Treating Ocular DiseasesUS Patent Applications (USPTO)
6y agoARPOAerpio Pharmaceuticals, Inc. (ARPO) Management on Q3 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
6y agoARPO GOSSAerpio Reports Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswireEnrollment completed in the 28-day Phase 2 razuprotafib glaucoma trial; topline data expected to be reported in December 2020 or possibly in early January 2021Initiated second clinical trial to...
6y agoARPOAerpio Hosting Key Opinion Leader Call on New Therapeutic Agents for COVID-19GlobeNewswireCINCINNATI, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc.("Aerpio") (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
6y agoARPOAerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10GlobeNewswireCINCINNATI, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
6y agoARPOAerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19GlobeNewswireThe trial in moderate-to-severe patients is Aerpio’s second clinical trial in COVID-19 patients and is funded in part by the U.S. military The military-sponsored trial is complementary to the...
6y agoARPOAerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma TrialGlobeNewswireCINCINNATI, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc.("Aerpio") (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
6y agoARPOAerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 PatientsGlobeNewswireSAN FRANCISCO and CINCINNATI, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today...
6y agoARPO GOSSAerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 PatientsPR NewswireAerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today dosing of the first...
6y agoARPOAerpio Pharmaceuticals' (ARPO) Management on Q2 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
6y agoARPOAerpio Reports Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswireInitiated a Phase 2 Open Angle Glaucoma Trial; Recruiting Ahead of ScheduleAnnounced Partnership with I-SPY to Participate in a Clinical Trial to Treat ARDS in COVID-19 PatientsAnnounced a Second...
6y agoARPOAerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12GlobeNewswireCINCINNATI, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
6y agoARPOAerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19GlobeNewswireCINCINNATI, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and The U.S. Government operating through the Medical Technology Enterprise Consortium (MTEC)...
6y agoARPOAerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma TrialGlobeNewswireCINCINNATI, June 24, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
6y agoARPOAerpio Announces Change to Virtual Format for its 2020 Annual Meeting of Stockholders due to COVID-19GlobeNewswireCINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ARPO), today announced that, due to the public health and safety concerns related to the novel...
6y agoARPOAerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 PatientsGlobeNewswireSAN FRANCISCO and CINCINNATI, May 27, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an...
6y agoARPO GOSSAerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 PatientsPR NewswireAerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement has...
6y agoARPOAerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)GlobeNewswireCINCINNATI, May 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular...
6y agoARPONew patent application published for: Compositions and Methods for Treating Ocular DiseasesUS Patent Applications (USPTO)( 1 of 1 )
6y agoARPONew patent application published for: Multispecific Antibodies That Target Hptp-B (ve-Ptp) and VegfUS Patent Applications (USPTO)( 1 of 1 )
6y agoARPOAerpio Pharmaceuticals, Inc. (ARPO) on Q4 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
6y agoARPO GOSSAerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdateGlobeNewswirePlan to advance AKB-9778 topical formulation into a Phase 2 trial in open angle glaucoma with top line results expected during the first quarter of 2021 Conference Call and Webcast Today, March 16,...
6y agoARPOAerpio Pharmaceuticals to Report Year Ended December 31, 2019 Financial Results on Monday, March 16, 2020GlobeNewswireCINCINNATI, March 12, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases...
6y agoARPO GOSSAerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular HypertensionBusiness WireCINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, announced that Kevin Peters, M.D., Aerpio’s Chief Scientific Officer, presented data from the fifth cohort of subjects from a Phase 1b trial showing the potential of a topical ocular formulation ...
6y agoARPO GOSSTopical Ocular Formulation of Aerpio Pharmaceutical’s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b TrialBusiness WireCINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced new results from the fifth cohort of subjects from a Phase 1b trial of a topical ocular formulation of AKB-9778 providing evidence of tolerability and IOP reduction from patients ...
7y agoARPO GOSSAerpio Reports Third Quarter 2019 Financial Results and Provides Business UpdateBusiness WireCINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the third quarter ended September 30, 2019, and provided a business update.
7y agoARPOAerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle GlaucomaBusiness WireCINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced interim results from its Phase 1b clinical trial of a topical ocular formulation of AKB-9778 in development as a potential treatment for primary open angle glaucoma (POAG).
7y agoARPOAerpio Reports Second Quarter 2019 Financial Results and Provides Business UpdateBusiness WireCINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the second quarter ended June 30, 2019, and provided a business update.
7y agoARPOAerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle GlaucomaBusiness WireCINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced dosing of the first subject in a Phase 1b trial of a topical ocular formulation of AKB-9778 in development for treatment of primary open angle glaucoma (POAG).
7y agoARPOAERPIO PHARMS INC (ARPO) Q4 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
8y agoARPOAerpio Pharmaceuticals' (ARPO) CEO Steve Hoffman on Q3 2018 Results - Earnings Call TranscriptEarnings Call Transcripts